Intermediate-high-risk pulmonary embolism (PE) is characterized by right ventricular (RV) dysfunction and elevated circulating cardiac troponin levels despite apparent hemodynamic stability at presentation. In these patients, full-dose systemic thrombolysis reduced the risk of hemodynamic decompensation or death but increased the risk of life-threatening bleeding. Reduced-dose thrombolysis may be capable of improving safety while maintaining reperfusion efficacy. The Pulmonary Embolism International THrOmbolysis (PEITHO)-3 study (ClinicalTrials.gov Identifier: NCT04430569) is a randomized, placebo-controlled, double-blind, multicenter, multinational trial with long-term follow-up. We will compare the efficacy and safety of a reduced-dose al...
Limited information exists about the prevalence, management, and outcomes of intermediate-high risk ...
BACKGROUND The role of fibrinolytic therapy in patients with intermediate-risk pulmonary embolism...
AIMS Catheter-directed treatment of acute pulmonary embolism (PE) is technically advancing. Recen...
Intermediate-high-risk pulmonary embolism (PE) is characterized by right ventricular (RV) dysfunctio...
Intermediate-high-risk pulmonary embolism (PE) is characterized by right ventricular (RV) dysfunctio...
Intermediate high-risk pulmonary embolism (PE) is characterised by right ventricular (RV) dysfunctio...
BACKGROUND: Due to the bleeding risk of full-dose systemic thrombolysis and the lack of major trials...
BACKGROUND Ultrasound-assisted catheter-directed thrombolysis (USAT) may reverse right ventricula...
Haemodynamic instability and right ventricular dysfunction are the key determinants of short-term pr...
Background: Multidisciplinary Pulmonary Embolism Response Teams (PERTs) were established to individu...
Pulmonary embolism (PE) is the third leading cause of cardiovascular death in the western world.Prom...
none37siBACKGROUND: The role of fibrinolytic therapy in patients with intermediate-risk pulmonary e...
Pulmonary embolism as a part of venous thromboembolic disease has a broad spectrum of clinical prese...
Limited information exists about the prevalence, management, and outcomes of intermediate-high risk ...
BACKGROUND The role of fibrinolytic therapy in patients with intermediate-risk pulmonary embolism...
AIMS Catheter-directed treatment of acute pulmonary embolism (PE) is technically advancing. Recen...
Intermediate-high-risk pulmonary embolism (PE) is characterized by right ventricular (RV) dysfunctio...
Intermediate-high-risk pulmonary embolism (PE) is characterized by right ventricular (RV) dysfunctio...
Intermediate high-risk pulmonary embolism (PE) is characterised by right ventricular (RV) dysfunctio...
BACKGROUND: Due to the bleeding risk of full-dose systemic thrombolysis and the lack of major trials...
BACKGROUND Ultrasound-assisted catheter-directed thrombolysis (USAT) may reverse right ventricula...
Haemodynamic instability and right ventricular dysfunction are the key determinants of short-term pr...
Background: Multidisciplinary Pulmonary Embolism Response Teams (PERTs) were established to individu...
Pulmonary embolism (PE) is the third leading cause of cardiovascular death in the western world.Prom...
none37siBACKGROUND: The role of fibrinolytic therapy in patients with intermediate-risk pulmonary e...
Pulmonary embolism as a part of venous thromboembolic disease has a broad spectrum of clinical prese...
Limited information exists about the prevalence, management, and outcomes of intermediate-high risk ...
BACKGROUND The role of fibrinolytic therapy in patients with intermediate-risk pulmonary embolism...
AIMS Catheter-directed treatment of acute pulmonary embolism (PE) is technically advancing. Recen...